Chin‐Hee Chung

425 total citations
16 papers, 307 citations indexed

About

Chin‐Hee Chung is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Chin‐Hee Chung has authored 16 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Chin‐Hee Chung's work include Lung Cancer Treatments and Mutations (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Chin‐Hee Chung is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Chin‐Hee Chung collaborates with scholars based in United States, Japan and Spain. Chin‐Hee Chung's co-authors include Jianying Zhou, Paulina Selaru, Yiyun Tang, Yuankai Shi, Tony Mok, Byoung Chul Cho, Keith D. Wilner, Shun Lü, Yi‐Long Wu and Chun‐Ming Tsai and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Clinical Pharmacology.

In The Last Decade

Chin‐Hee Chung

13 papers receiving 303 citations

Peers

Countries citing papers authored by Chin‐Hee Chung

Since Specialization

Citations

This map shows the geographic impact of Chin‐Hee Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chin‐Hee Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chin‐Hee Chung more than expected).

Fields of papers citing papers by Chin‐Hee Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chin‐Hee Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chin‐Hee Chung. The network helps show where Chin‐Hee Chung may publish in the future.

Co-authorship network of co-authors of Chin‐Hee Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Chin‐Hee Chung. A scholar is included among the top collaborators of Chin‐Hee Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chin‐Hee Chung. Chin‐Hee Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Abstract P5-08-28: Randomized phase 2 window of opportunity trial comparing the effect of preoperative atirmociclib (PF-07220060) plus letrozole versus letrozole alone on Ki-67 tumor expression in postmenopausal women with HR+/HER2+ breast cancer 2025 ·Clinical Cancer Research ·Sanjay Goel, Khalil Zaman, (unknown), Ahmed Elkhanany, Chiun‐Sheng Huang, (unknown), Sara López‐Tarruella, Chin‐Hee Chung, (unknown), Yuan Liu, Cynthia Basu, Michail Ignatiadis	0
2	SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). 2023 ·Journal of Clinical Oncology ·Scott Kopetz, Tanios Bekaii‐Saab, Takayuki Yoshino, Chin‐Hee Chung, Xiaosong Zhang, Josep Tabernero	3
3	BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAF^V600E metastatic colorectal cancer (mCRC). 2023 ·Journal of Clinical Oncology ·Scott Kopetz, Takayuki Yoshino, Tae Won Kim, Rona Yaeger, Jayesh Desai, Harpreet Wasan, Eric Van Cutsem, Fortunato Ciardiello, Tim Maughan, Cathy Eng, Jeanne Tie, Élena Elez, Sara Lonardi, (unknown), Chin‐Hee Chung, Tiziana Usari, (unknown), Danielle Murphy, Josep Tabernero	14
4	The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib 2022 ·Clinical Drug Investigation ·Joseph Piscitelli, Joseph Chen, Robert R. LaBadie, (unknown), Chin‐Hee Chung, Weiwei Tan	4
5	BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF^V600E) metastatic colorectal cancer (mCRC). 2022 ·Journal of Clinical Oncology ·Scott Kopetz, Takayuki Yoshino, Tae Won Kim, Jayesh Desai, Rona Yaeger, Eric Van Cutsem, Fortunato Ciardiello, Harpreet Wasan, Tim Maughan, Yuanyuan Zhang, Tiziana Usari, Chin‐Hee Chung, Xiaosong Zhang, Josep Tabernero	11
6	SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). 2022 ·Journal of Clinical Oncology ·Scott Kopetz, Tanios Bekaii‐Saab, Takayuki Yoshino, Chin‐Hee Chung, Xiaosong Zhang, Josep Tabernero	8
7	Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours 2019 ·British Journal of Clinical Pharmacology ·Mohamed Elmeliegy, István Láng, Е. А. Smolyarchuk, Chin‐Hee Chung, Anna Plotka, Haihong Shi, Diane Wang	21
8	A Phase 1 Mass Balance Study of ¹⁴C‐Labeled Talazoparib in Patients With Advanced Solid Tumors 2019 ·The Journal of Clinical Pharmacology ·Yanke Yu, Chin‐Hee Chung, Anna Plotka, (unknown), Haihong Shi, Zsuzsanna Pápai, Linh T. Nguyen, Diane Wang	16
9	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Yi‐Long Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Byoung Chul Cho, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang, Elizabeth T. Masters, Paulina Selaru, Tony Mok	137
10	P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy 2017 ·Journal of Thoracic Oncology ·You Lu, Jianying Zhou, Chin‐Hee Chung, Elizabeth T. Masters, Keith D. Wilner, Paulina Selaru, Yiyun Tang, Yi‐Long Wu	0
11	P3.02a-014 Patient Reported General Health Status in a Study of Crizotinib Versus Chemotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) 2017 ·Journal of Thoracic Oncology ·Jianying Zhou, You Lu, Chin‐Hee Chung, Elizabeth T. Masters, Keith D. Wilner, Yiyun Tang, Yi‐Long Wu	0
12	Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). 2016 ·Journal of Clinical Oncology ·Shun Lü, Tony Mok, You Lu, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Byoung Chul Cho, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang, Elizabeth T. Masters, Paulina Selaru, Yi‐Long Wu	12
13	A phase II study of single agent OSI-7904L in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) 2009 ·Journal of Clinical Oncology ·(unknown), Marshall R. Posner, Chin‐Hee Chung, John D. Hainsworth, (unknown), (unknown), Michael K. Gibson	4
14	Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933] 2008 ·BMC Neurology ·Francisco Martinez-Torres, Sanjay Menon, Maria Pritsch, N. Victor, Ekkehart Jenetzky, Katrin Jensen, Eva Schielke, Erich Schmutzhard, Jan de Gans, Chin‐Hee Chung, Steffen Luntz, Werner Hacke, Uta Meyding‐Lamadé, (unknown)	66
15	The impact of giving neo-adjuvant chemotherapy for patients with non-small cell lung cancer (NSCLC) : data from the MRC LU22/NVALT/EORTC 08012 randomised clinical trial 2005 ·European Journal of Cancer Supplements ·(unknown), Harry J.M. Groen, Jan P. van Meerbeeck, David Gilligan, Peter Goldstraw, C. Manegold, M. Nicolson, Chin‐Hee Chung, (unknown), Richard Stephens	2
16	Dose dependent effect of cimetidine on procainamide disposition in man. 1988 ·PubMed ·(unknown), Fengjuan Jiang, Chin‐Hee Chung, (unknown), P.-D.L. Chao	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact